Precigen's stock fell due to the FDA approval of a rival RRP treatment, Voceryq, intensifying competition. Despite this, Precigen's Papzimeos retains a commercial lead and strong clinical data, making upcoming earnings crucial for investor sentiment.
Precigen's stock experienced a sharp decline following the FDA approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis (RRP). This development introduces a significant competitive threat to Precigen's Papzimeos, which had enjoyed a commercial head start since its August 2025 approval. While Papzimeos boasts strong patient registrations, payer coverage, and long-term clinical data, the entry of a rival product creates uncertainty regarding future market share and revenue growth. Investors will be closely watching Precigen's upcoming third-quarter earnings report for insights into how the company plans to navigate this new competitive landscape and maintain its market position, making it a key short-term catalyst.